177 related articles for article (PubMed ID: 34422723)
1. Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review.
Daou KN; Barhoumi A; Bassyouni A; Karam PE
Front Pediatr; 2021; 9():698577. PubMed ID: 34422723
[No Abstract] [Full Text] [Related]
2. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
3. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
4. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
5. Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.
Dweikat I; Qawasmi N; Najeeb A; Radwan M
Metabol Open; 2021 Mar; 9():100083. PubMed ID: 33598652
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).
Das AM
Appl Clin Genet; 2017; 10():43-48. PubMed ID: 28769581
[TBL] [Abstract][Full Text] [Related]
7. Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening.
Hajji H; Imbard A; Spraul A; Taibi L; Barbier V; Habes D; Brassier A; Arnoux JB; Bouchereau J; Pichard S; Sissaoui S; Lacaille F; Girard M; Debray D; de Lonlay P; Schiff M
Mol Genet Metab Rep; 2022 Dec; 33():100933. PubMed ID: 36393896
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.
Aktuglu Zeybek AC; Kiykim E; Neselioglu S; Iscan HZ; Zubarioglu T; Cansever MS; Erel O
Pediatr Res; 2022 Aug; 92(2):474-479. PubMed ID: 34628487
[TBL] [Abstract][Full Text] [Related]
9. Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I.
Simoncelli M; Samson J; Bussières JF; Lacroix J; Dorais M; Battista R; Perreault S
Can J Hosp Pharm; 2015; 68(3):210-7. PubMed ID: 26157182
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of hereditary tyrosinemia in Japan.
Nakamura K; Matsumoto S; Mitsubuchi H; Endo F
Pediatr Int; 2015; 57(1):37-40. PubMed ID: 25443793
[TBL] [Abstract][Full Text] [Related]
11. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.
Tang Y; Kong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):514-523. PubMed ID: 34704422
[TBL] [Abstract][Full Text] [Related]
12. Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation.
Dehghani SM; Haghighat M; Imanieh MH; Karamnejad H; Malekpour A
Int J Prev Med; 2013 Dec; 4(12):1380-5. PubMed ID: 24498493
[TBL] [Abstract][Full Text] [Related]
13. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
14. Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.
Honar N; Shakibazad N; Serati Shirazi Z; Dehghani SM; Inaloo S
Iran J Child Neurol; 2017; 11(4):66-70. PubMed ID: 29201126
[TBL] [Abstract][Full Text] [Related]
15. Liver Transplant for Children With Hepatocellular Carcinoma and Hereditary Tyrosinemia Type 1.
Bahador A; Dehghani SM; Geramizadeh B; Nikeghbalian S; Bahador M; Malekhosseini SA; Kazemi K; Salahi H
Exp Clin Transplant; 2015 Aug; 13(4):329-32. PubMed ID: 24679101
[TBL] [Abstract][Full Text] [Related]
16. Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion.
Jack RM; Scott CR
JIMD Rep; 2019 Mar; 46(1):75-78. PubMed ID: 31240158
[TBL] [Abstract][Full Text] [Related]
17. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Tyrosinemia Type 1 in Indian Children.
Mirani S; Poojari V; Shetty NS; Shah I
J Clin Exp Hepatol; 2021; 11(1):9-13. PubMed ID: 33679043
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
